Table 12Cardiovascular disease-related mortality outcomes in subjects with the risk factor of dysglycemia. (Note: Annualized risk, unadjusted annualized RR, risk difference on annual data and AR for the study duration (%) are presented across the five diagnostic categories—IGT, IFG, I-IGT, I-IFG and combined IGT/IFG.)

Study GroupAuthorStudy Duration (y)Mortality TypeBaseline (n) IGT and/or IFGBaseline (n) NGT and/or NFGAnnualized Risk per 100 persons in exposed populationAnnualized Relative Risk (95% CI)Annualized Risk Difference per 100 persons% Attributable Risk in exposed population for study duration
MortalityMortality
YesNoYesNo
Risk group: IGT
Tominaga, 199993 7CVD113711919970.423.080.2867.3
(1.47–6.47)
NHANES IISaydah, 200192 16CVD5542515921040.761.670.3038.7
(1.23–2.26)
PPSBalkau, 199155 18Ischemic heart disease77004661290.061.330.0124.8
(0.60–2.95)
Risk group: IGT (isolated)
PPSBalkau, 199259 18Cardio-cerebrovas-cular4063821058430.341.720.1441.2
(1.23–2.41)
CHD2865015858950.231.590.0936.8
(1.07–2.28)
Risk group: IFG
CAREGoldberg, 199852 5CHD121497114781.541.650.6038.5
RCT(0.90–3.02)
Tominaga, 199993 7CVD - 7yr31522722800.281.660.1139.5
(0.50–5.46)
BIPFisman, 200191 9CVD - Ischemic79117946993050.721.320.1723.6
(1.04–1.67)
BIPTenenbaum, 200289 9Cardiac172119017230.861.520.2933.4
(0.91–2.55)
PPSBalkau, 200243 17Coronary53120919353210.251.200.0416.7
(0.89–1.63)
CVD77112630752750.391.170.0614.1
(0.91–1.50)
Ischemic2112148253850.101.130.0111.8
(0.70–1.83)
Risk group: IFG (isolated)
None
Risk group: Multiple IGT/IFG
None

Abbreviations: BIP=Bezafibrate Infarction Prevention trial; CHD=Cholesterol and Recurrent Events Study; CHD=Coronary heart disease; CVD=Cardiovascular disease; IFG=Impaired fasting glucose; IGT=Impaired glucose tolerance; I-IFG=Isolated impaired fasting glucose; I-IGT=Isolated impaired glucose tolerance; NHANES=National Health and Nutrition Examination Survey; PPS=Paris Prospective Study; y=Year(s)

From: 3, Results

Cover of Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose
Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose.
Evidence Reports/Technology Assessments, No. 128.
Santaguida PL, Balion C, Hunt D, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.